Data & Technology

The legislation’s deadline for compliance is knocking on the door. Pharma Commerce offers a synopsis of how the Drug Supply Chain Security Act has progressed over the past decade.

In this latest Harvard Business School Healthcare Alumni Association Q&A, Ayelet Israeli, PhD, explains the potential—as well as limitations—of these offerings and pragmatic guardrails for deployment in organizations.

Using AI and data science, ‘plai’ is expected to assist employees with making everyday decisions, including the manufacturing of vaccines.

Biopharmas are able to industry insight to assist them across the end-to-end product lifecycle.

Software company’s branded orchestration platform helps to track chain of identity and chain of custody.

While generics and adherence challenges are keeping drugmakers up at night, breakthroughs in the pipeline coupled with innovative uses of artificial intelligence and machine learning techniques are bringing optimism to the cardiovascular disease space.

The latest IT offerings for sales force automation—including new AI tools—promise a more effective pharma sales process.

How pharma can harness digitalization all the way through commercialization

In effort to authenticate doctors’ information, AI-powered product strives to not only improve compliance, but also increase satisfaction among members and providers.

The products, cloud revenue management solution provider says, are aimed at addressing supply chain challenges.

Purchase of SPORIFY enhances software company’s E2E branded platform, with the addition of data governance enhancements.

How maximizing the intelligence gained from brand engagement compliance activities can help drive pharmaceutical company commercial decisions.

Johnson & Johnson VP comments on building digital capabilities into workflows.

Expert panel identifies five key areas where patient-centric strategies can benefit supply chains the most—and lead to better patient outcomes.

Multi-enterprise information tower to facilitate exchange of interoperable commerce, inventory, logistics, and other supply chain data.

In this latest Harvard Business School Healthcare Alumni Association Q&A, Dr. Peter Cappelli, Professor of Management at The Wharton School and Director of Wharton’s Center for Human Resources, explains how biopharma C-suites can lead their teams through 2023’s turbulent times.

Joint initiative integrates submitted claims with parties’ platforms in effort to avoid duplicate data.

Innovation and investment in advancing lifesaving therapies for pediatric patients to the commercial stage remains a daunting task, but rapid advances today in modeling and simulation are reducing the hurdles for drugmakers.

How molding these elements into one can add efficiencies to work processes.

With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.

Deciphering the different "technology-first” and “technology-enabled” patient support programs.

Why deploying AI and analytics in tandem is a key targeting tool.

Why automation-enabling tech—such as NLP and ML—can help improve medicine effectiveness.

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

In an effort to strengthen supply chain, unnamed pharma company to use chain of custody application to combat an illegal global market worth up to $200 billion annually.

Acquisition expands company’s eCTD submission capabilities.

Site expected to support growth of advanced analytics and data science team.

Conclusion driven by various factors, including product shortages and cost pressures.

Meanwhile, PDG issues more DSCSA guidance on data interoperability.

How artificial intelligence and real-world data has not just helped predict patient behavior, but has also been successful at the point-of-care for life sciences companies.